-

10:43:04 PM

LIVE Real Time NVCR Stock Market News

NVCR - NovoCure Ltd

04/29/21 6:00 AM

Nasdaq : NVCR

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven by COVID-19, as well as continued progress across the company's clinical and product development

RHEA-AI

neutral

04/22/21 8:47 AM

Nasdaq : NVCR

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also announced the

RHEA-AI

very positive

04/13/21 7:30 AM

Nasdaq : NVCR

Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC),

RHEA-AI

neutral

04/09/21 7:30 AM

Nasdaq : NVCR

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Research spanning seven solid tumor

RHEA-AI

negative

04/01/21 6:00 AM

Nasdaq : NVCR

Novocure to Report First Quarter 2021 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure's management will host a conference call and webcast to discuss its financial results for the three months ended

RHEA-AI

neutral

02/25/21 6:00 AM

Nasdaq : NVCR

Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2020, highlighting revenue growth and financial strength as well as the advancement of the company's clinical and product development programs. Novocure is a global oncology company working to

RHEA-AI

positive

02/08/21 4:00 PM

Nasdaq : NVCR

Novocure Announces Addition to Its Board of Directors

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure's board on Feb. 5."We are extremely pleased to welcome Tim to our board of directors," said Bill Doyle, Novocure's Executive Chairman. "His

RHEA-AI

neutral

01/11/21 6:00 AM

Nasdaq : NVCR

Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update

Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. Novocure also plans

RHEA-AI

neutral

12/23/20 7:30 AM

Nasdaq : NVCR

Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference

Novocure (NASDAQ: NVCR) will participate virtually in the 39 th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure's Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. EST on January 12,

RHEA-AI

neutral

12/14/20 1:00 AM

Nasdaq : NVCR

Novocure Announces National Reimbursement in Switzerland for Optune(R) in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of

RHEA-AI

neutral